The present review article strives to assess the safety and benefits of incretin-based therapy, a new class of antidiabetic drug, on the health of patient cardiovascular systems
Rare but serious gastrointestinal complications have been reported in post-marketing surveillance, including: Acute pancreatitis : If suspected, the GLP-1 agonist should be stopped immediately and not restarted if pancreatitis is confirmed Severe gastroparesis : Rare post-marketing reports of severe delayed gastric emptying Intestinal obstruction : Very rare cases reported in post-marketing surveillance Patients should be advised to seek urgent medical help via NHS 111, A&E or 999 as appropriate if they experience severe or persistent abdominal pain, persistent vomiting, abdominal distension, inability to pass stool or gas, or bloody diarrhoea whilst taking GLP-1 agonists
Ducheix S, Vegliante MC, Villani G, Napoli N, Sabba C, Moschetta A (2016) Is hepatic lipogenesis fundamental for NAFLD/NASH
Reduce Cravings Reduce cravings by acting on areas of the brain that regulate hunger and reward signals
S1a, Supplementary Table 1) 13
The drug has shown effectiveness in supporting weight loss when combined with a healthy diet and exercise